A new randomized controlled trial among BRCA1/2 carriers comparing neoadjuvant chemotherapy with olaparib versus chemotherapy alone found:
- No improvement in pathological complete response (64.1% with olaparib versus 69.8% with chemotherapy alone)
- Yet significant improvement in overall survival (100% at 3 years with olaparib versus 88.2% with chemotherapy alone)
- Superior event-free and breast cancer specific survival
These findings suggest that adding olaparib may benefit survival for BRCA1/2 carriers, even if this is not apparent when looking at pathologic response.
Abraham, et al. Nat Commun. 2025;16(1):4269. PMID: 40360463. Article available at: https://pubmed.ncbi.nlm.nih.gov/40360463/. Social media post available at: https://www.facebook.com/share/p/1CRyyzRq1e/